SM-020 is under clinical development by DermBiont and currently in Phase II for Dermatological Disorders. According to GlobalData, Phase II drugs for Dermatological Disorders does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the SM-020 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SM-020 is under development for the treatment of seborrheic keratosis. It is a gel form administered by the topical route. It acts by targeting protein kinase B (Akt).
DermBiont, Inc., a clinical stage precision dermatology company targeting skin diseases at their root cause. The company is headquartered in United States.
For a complete picture of SM-020’s drug-specific PTSR and LoA scores, buy the report here.